USPTO serial 88636131
MORPHOMER
Reviewed by CopyMark Law Group
Status 653
- Filing date
- Status date
- Registration date
- —
- Examiner
- DETMER, CAROLYN ROSE
- Law office
- TMO LAW OFFICE 127
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with MORPHOMER?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Kristina Montanaro Schrader
Kristina Montanaro Schrader Adams and Reese LLP1600 West End AvenueSuite 1400Nashville, TN 37203Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemicals for use in industry and science; chemical substances, chemical materials and chemical preparations, and natural elements, namely, chemical preparations for industrial and scientific purposes, other than for medical or veterinary use; chemical, biochemical, biological and biotechnological preparations for use in industry and science; chemical preparations comprising small molecules for use in industry and science; molecular libraries, comprising libraries of chemical preparations for use in industry and science; small molecule library, comprising libraries of chemical preparations for use in industry and science; detectably labelled compound for industrial, scientific purposes; diagnostic reagents for industrial, scientific or research purposes; immunological reagents for industrial, scientific or research purposes; diagnostic tools in the nature of preparations, companion diagnostic agents, biomarkers, imaging agents, PET-Imaging compounds for industrial, scientific purposes other than for medical or veterinary use; diagnostic reagents for industrial, scientific or research purposes other than for medical or veterinary use; none of the foregoing in relation to and for antibodies | ACTIVE | — |
| 005 | Pharmaceuticals, medical and veterinary preparations for the diagnosis, prevention and treatment of neurodegenerative diseases and inflammatory diseases; diagnostic preparations and materials for medical or veterinary purposes; companion diagnostic agents, biomarkers, imaging agents, PET-Imaging compounds, all for medical purposes; chemical preparations for medical purposes, namely, for the diagnosis, prevention and treatment of neurodegenerative diseases and inflammatory diseases; chemico-pharmaceutical preparation for medical purposes, namely, for the diagnosis, prevention and treatment of neurodegenerative diseases and inflammatory diseases; pharmaceutical and medical preparations in the nature of small molecule compounds for medical purposes; PET-Imaging compounds in the nature of diagnostic radiopharmaceutical agents for use in PET imaging; diagnostic preparations in the nature of companion compounds for medical use; pharmaceutical and medical preparations in the nature of biomarkers for medical purposes; diagnostic reagents for medical purposes; none of the foregoing in relation to and for antibodies | ACTIVE | — |
| 042 | Scientific and technological services, namely, scientific research, analysis and testing and the development of technology in the field of medicine and pharmaceuticals and research activities relating thereto; providing access to a proprietary technology platform containing small molecules that gives users the ability to obtain information for research purposes; biological research services; chemical research services in the fields of neurodegenerative diseases and inflammatory diseases; medical research services; scientific and medical laboratory services in biotechnology, chemistry, pharmacy, molecular science and immunotherapy; providing medical and scientific research information in the field of biotechnology, chemistry, pharmacy, molecular science, immunotherapy, therapeutics, diagnostics and clinical trials; scientific research, development and consultancy in the field of biotechnology, chemistry, pharmacy, molecular science, immunotherapy, therapeutics, diagnostics and clinical trials; development of test procedures, assays, test reagents, PET-imaging, companion diagnostic biomarkers, and test kits for the field of biotechnology, chemistry, pharmacy, molecular science, immunotherapy, therapeutics, diagnostics and clinical trials; biological research, namely, screening and selection of pharmaceutical active substances from biological and biotechnological preparations; custom design and development of biological assays; none of the foregoing in relation to and for antibodies | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 9, 2026 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Oct 9, 2026 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Oct 9, 2026 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Oct 1, 2026 | ACEC | AMENDMENT FROM APPLICANT ENTERED | — |
| Oct 1, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 30, 2026 | ERSI | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | — |
| Jun 30, 2026 | GNS2 | NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED | — |
| Jun 30, 2026 | GNSI | INQUIRY TO SUSPENSION E-MAILED | — |
| Jun 30, 2026 | CNSI | SUSPENSION INQUIRY WRITTEN | — |
| Jun 26, 2026 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| Nov 7, 2025 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Nov 7, 2025 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Nov 7, 2025 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Nov 7, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Nov 7, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Nov 5, 2025 | ERSI | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | — |
| Sep 10, 2025 | GNS2 | NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED | — |
| Sep 10, 2025 | GNSI | INQUIRY TO SUSPENSION E-MAILED | — |
| Sep 10, 2025 | CNSI | SUSPENSION INQUIRY WRITTEN | — |
| Jun 4, 2025 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| Dec 3, 2024 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| Dec 2, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 2, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 2, 2024 | ERSI | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | — |
| Jun 19, 2024 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Jun 19, 2024 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Jun 19, 2024 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Jun 18, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jun 18, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jun 18, 2024 | ALIE | ASSIGNED TO LIE | — |
| May 16, 2024 | ERSI | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | — |
| Feb 28, 2024 | GNS2 | NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED | — |
| Feb 28, 2024 | GNSI | INQUIRY TO SUSPENSION E-MAILED | — |
| Feb 28, 2024 | CNSI | SUSPENSION INQUIRY WRITTEN | — |
| Dec 6, 2023 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| Dec 4, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Nov 30, 2022 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| Apr 27, 2022 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Apr 27, 2022 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Apr 27, 2022 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Feb 14, 2022 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Feb 14, 2022 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 14, 2022 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Feb 9, 2022 | ALIE | ASSIGNED TO LIE | — |
| Jan 31, 2022 | ALIE | ASSIGNED TO LIE | — |
| Jan 27, 2022 | ERSI | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | — |
| Jan 27, 2022 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jan 27, 2022 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 27, 2022 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Aug 10, 2021 | GNS2 | NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED | — |
| Aug 10, 2021 | GNSI | INQUIRY TO SUSPENSION E-MAILED | — |
| Aug 10, 2021 | CNSI | SUSPENSION INQUIRY WRITTEN | — |
| Jul 6, 2021 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| Jul 29, 2020 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Jul 29, 2020 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Jul 29, 2020 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Jul 3, 2020 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 3, 2020 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 3, 2020 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 6, 2020 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 6, 2020 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 6, 2020 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 3, 2020 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 3, 2019 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Oct 3, 2019 | NWAP | NEW APPLICATION ENTERED | — |